Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Carcinoma, Non-Small-Cell Lung 53Lung Neoplasms 24Breast Neoplasms 22Head and Neck Neoplasms 14Adenocarcinoma of Lung 11Neoplasms 7Esophageal Neoplasms 7Brain Neoplasms 7Prostatic Neoplasms 6Adenocarcinoma, Bronchiolo-Alveolar 6Neoplasm Metastasis 5Glioblastoma 5Adenocarcinoma Of Esophagus 5Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Ovarian Neoplasms 4Gliosarcoma 4Colorectal Neoplasms 4Colonic Neoplasms 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Skin Neoplasms 2Neoplasms, Squamous Cell 2Mesothelioma, Malignant 2Lymphoid Interstitial Pneumonia 2Laryngeal Diseases 2

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 25Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × Gefitinib × Clear all
NCT00483561 2023-09-13

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

University of Nebraska

Phase 2 Terminated
26 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT00025116 2020-04-06

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Canadian Cancer Trials Group

Phase 2 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT00265070 2013-02-05

Trial of Iressa in Prostate Cancer Patients

AstraZeneca

Phase 2 Completed
80 enrolled
Genitourinary

Prostatic Neoplasms

NCT00242918 2012-02-07

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

Benaroya Research Institute

Phase 2 Completed
29 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT00241475 2009-04-23

Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy

AstraZeneca

Phase 2 Completed
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT00635856 2009-04-23

Open Label Trial to Assess Iressa in Prostate Cancer Patients

AstraZeneca

Phase 2 Completed
100 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡